17 completed, 3 recruiting, 2 terminated, 2 unknown. 25 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 17, Recruiting 3, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Unknown 2, Terminated 1 |
Follow Cholangitis: new trials by email Literature Review of Cholangitis trials Research Report on Cholangitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) TAK-781, Placebo - Healthy Volunteers, Primary Sclerosing Cholangitis | Phase 1 | Recruiting | Takeda | 134 | 2026-01-07 | 2026-03-05 |
| A Study of SIPLIZUMAB in AILD and LT Patients Siplizumab - Autoimmune Liver Disease, Liver Transplant Disorder | Phase 1 | Recruiting | Elizabeth C. Verna | 8 | 2024-09-11 | 2025-11-24 |
| Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 CS0159 - Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | Cascade Pharmaceuticals, Inc | 79 | 2021-10-26 | 2022-10-18 |
| Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Cilofexor - Primary Sclerosing Cholangitis, Compensated Cirrhosis | Phase 1 | Terminated | Gilead Sciences | 11 | 2019-10-17 | 2023-07-27 |
| Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects CM-101, Placebo - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | ChemomAb Ltd. | 8 | 2019-03-05 | 2023-09-14 |
| Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH Orbcel-C - Cholangitis, Sclerosing, Hepatitis, Autoimmune | Phase 1 / Phase 2 | Unknown | University of Birmingham | 18 | 2018-12-07 | 2024-07-11 |
| A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Ursolic acid - Primary Sclerosing Cholangitis | Phase 1 | Withdrawn | University of California, Davis | 2017-09-01 | 2017-07-25 | |
| A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC) Curcumin - Primary Sclerosing Cholangitis | Phase 1 / Phase 2 | Completed | John E. Eaton | 15 | 2017-06-09 | 2020-01-18 |
| A Study of HTD1801 in Healthy Subjects HTD1801 - Primary Sclerosing Cholangitis | Phase 1 | Completed | HighTide Therapeutics (Hong Kong) Limited | 32 | 2017-03-24 | 2026-08-11 |
| Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis UCMSC, UDCA - Primary Sclerosing Cholangitis | Phase 1 / Phase 2 | Unknown | Fuzhou General Hospital | 20 | 2017-01-01 | 2018-05-04 |
| Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Cilofexor - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | Gilead Sciences | 57 | 2016-07-13 | 2021-01-07 |
| Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Fecal Microbiota Transplantation - Sclerosing Cholangitis | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 10 | 2016-02-01 | 2019-08-28 |
| A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Vancomycin - Primary Sclerosing Cholangitis, Inflammatory Bowel Disease | Phase 1 | Completed | University of Minnesota | 8 | 2015-07-01 | 2020-07-17 |
| Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT 11C-CSar, ICG - Cholestasis, Primary Sclerosing Cholangitis | Phase 1 | Completed | University of Aarhus | 22 | 2013-06-01 | 2015-02-23 |
| A Pilot Study of Xifaxan to Treat Patients With PSC Xifaxan - Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | Mayo Clinic | 16 | 2012-08-01 | 2014-10-15 |
| Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis Oral all-trans retinoic acid (ATRA) - Cholangitis, Sclerosing | Phase 1 | Completed | Yale University | 19 | 2011-10-01 | 2016-07-14 |
| Pilot Study of Fenofibrate for PSC fenofibrate - Primary Sclerosing Cholangitis | Phase 1 / Phase 2 | Terminated | University of Miami | 8 | 2010-10-01 | 2018-02-06 |
| Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis ursodeoxycholic acid (UDCA) - Primary Sclerosing Cholangitis | Phase 1 | Completed | University of Tennessee | 27 | 2010-10-01 | 2017-10-26 |
| Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin Oral Vancomycin - Primary Sclerosing Cholangitis, Biliary Atresia | Phase 1 | Recruiting | Sacramento Pediatric Gastroenterology | 200 | 2010-07-01 | 2016-11-15 |
| A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis Vancomycin, Metronidazole - Primary Sclerosing Cholangitis | Phase 1 | Completed | Mayo Clinic | 35 | 2010-02-01 | 2013-09-19 |
Showing 20 of 25. Sign in to see all of them.
Cholangitis, Sclerosing (25) · Hepatitis, Autoimmune (3) · Biliary Atresia (2) · Fibrosis (2) · Liver Cirrhosis, Biliary (2) · Non-alcoholic Fatty Liver Disease (2) · Cholangiocarcinoma (1) · Cholestasis (1) · Colitis (1) · End Stage Liver Disease (1) · Gastrointestinal Diseases (1) · Inflammatory Bowel Diseases (1) · Liver Cirrhosis (1) · Liver Diseases (1)
Bile Duct Diseases (25) · Biliary Tract Diseases (25) · Digestive System Diseases (25) · Liver Diseases (6) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Autoimmune Diseases (3) · Hepatitis (3) · Hepatitis, Chronic (3) · Immune System Diseases (3) · Cholestasis, Intrahepatic (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Abnormalities (2)
Vancomycin (4) · cilofexor (2) · Budesonide (1) · Curcumin (1) · Docosahexaenoic Acids (1) · Erlotinib Hydrochloride (1) · Fecal Microbiota Transplantation (1) · Fenofibrate (1) · Fish Oils (1) · Indocyanine Green (1) · Metronidazole (1) · Minocycline (1) · Rifaximin (1) · Tretinoin (1) · Ursodeoxycholic Acid (1)
Mayo Clinic (4) · Gilead Sciences (2) · Beth Israel Deaconess Medical Center (1) · Brigham and Women's Hospital (1) · Cascade Pharmaceuticals, Inc (1) · ChemomAb Ltd. (1) · Elizabeth C. Verna (1) · Fuzhou General Hospital (1) · HighTide Therapeutics (Hong Kong) Limited (1) · John E. Eaton (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Sacramento Pediatric Gastroenterology (1) · Stanford University (1) · Takeda (1) · University of Aarhus (1)
United States (19) · Australia (1) · Denmark (1) · Israel (1) · New Zealand (1) · United Kingdom (1)
Arnon Aharon, MD (1) · Benjamin Shneider, M.D. (1) · Byron P Vaughn, MD (1) · Christopher Bowlus, MD (1) · Cynthia Levy, MD (1) · Dennis D Black, M.D. (1) · Elizabeth Verna, MD (1) · James L Boyer, MD (1) · Janet Wong, Doctor (1) · Jayant A Talwalkar, MD (1) · Jayant Talwalkar, MD (1) · Joshua Korzenik, MD (1) · Kathleen Doisy, MD (1) · Keith D. Lindor (1)
PMID 10655252, PMID 23054338, PMID 23384404, PMID 24914504, PMID 28249726, PMID 32633158, PMID 38976363, PMID 42271063
R03DK052344 (1), R03DK071851 (1)